BR112019023141A2 - métodos de tratamento seletivo da asma usando antagonistas de il-17 - Google Patents

métodos de tratamento seletivo da asma usando antagonistas de il-17 Download PDF

Info

Publication number
BR112019023141A2
BR112019023141A2 BR112019023141-2A BR112019023141A BR112019023141A2 BR 112019023141 A2 BR112019023141 A2 BR 112019023141A2 BR 112019023141 A BR112019023141 A BR 112019023141A BR 112019023141 A2 BR112019023141 A2 BR 112019023141A2
Authority
BR
Brazil
Prior art keywords
seq
patient
antagonist
treatment
immunoglobulin
Prior art date
Application number
BR112019023141-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Sarah Schmidt Grant
Shamsah Kazani
Edward Khokhlovich
Jason Laramie
Robert Martin Strieter
Tricia Ann Thornton-Wells
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112019023141A2 publication Critical patent/BR112019023141A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112019023141-2A 2017-05-05 2018-05-04 métodos de tratamento seletivo da asma usando antagonistas de il-17 BR112019023141A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (1)

Publication Number Publication Date
BR112019023141A2 true BR112019023141A2 (pt) 2020-07-28

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023141-2A BR112019023141A2 (pt) 2017-05-05 2018-05-04 métodos de tratamento seletivo da asma usando antagonistas de il-17

Country Status (13)

Country Link
US (1) US10676522B2 (https=)
EP (1) EP3619536A1 (https=)
JP (1) JP2020518604A (https=)
KR (1) KR20190142398A (https=)
CN (1) CN110582702A (https=)
AU (1) AU2018263159A1 (https=)
BR (1) BR112019023141A2 (https=)
CA (1) CA3062179A1 (https=)
CL (1) CL2019003161A1 (https=)
MX (1) MX2019013160A (https=)
RU (1) RU2019139387A (https=)
TW (1) TW201842933A (https=)
WO (1) WO2018203289A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN115362173A (zh) * 2020-04-17 2022-11-18 伊莱利利公司 呼吸系统疾病的治疗

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
BRPI0906261A2 (pt) 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
NZ591484A (en) 2008-09-29 2012-09-28 Roche Glycart Ag Antibodies against human il 17 and uses thereof
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
WO2015191783A2 (en) * 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CN115957326A (zh) * 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
CN110582702A (zh) 2019-12-17
CA3062179A1 (en) 2018-11-08
WO2018203289A1 (en) 2018-11-08
TW201842933A (zh) 2018-12-16
US20180319881A1 (en) 2018-11-08
AU2018263159A1 (en) 2019-11-07
MX2019013160A (es) 2020-02-05
CL2019003161A1 (es) 2020-02-07
EP3619536A1 (en) 2020-03-11
JP2020518604A (ja) 2020-06-25
US10676522B2 (en) 2020-06-09
KR20190142398A (ko) 2019-12-26
RU2019139387A (ru) 2021-06-07

Similar Documents

Publication Publication Date Title
JP7842268B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2026063214A (ja) 高濃度抗ｃ５抗体製剤
CN105517570B (zh) 通过施用il-4r拮抗剂治疗鼻息肉症的方法
KR20200088857A (ko) Il-17 길항제에 의한 화농성 한선염의 치료
US20230235069A1 (en) Treatment of atopic dermatitis
JP7589045B2 (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
US10676522B2 (en) Methods of selectively treating asthma using IL-17 antagonists
CA3173007A1 (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
US20220348687A1 (en) Dosing for anti-tryptase antibodies
IL295545A (en) Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
US20230242652A1 (en) Treatments for atopic dermatitis
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
JP7343547B2 (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2024521474A (ja) 皮膚筋炎（ｄｍ）を治療するための抗ｃ５抗体の投与量及び投与
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
US20240261380A1 (en) Methods of treating atopic dermatitis
WO2025210099A1 (en) Method of treatment and selecting a subject
CN121443637A (zh) 用于治疗斑块状银屑病的方法和组合物
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
HK40104675A (zh) 异位性皮肤炎的治疗
HK40100361A (zh) 用抗il-13抗体治疗特应性皮炎的方法
BR122019023269B1 (pt) composição farmacêutica compreendendo um anticorpo que se liga especificamente ao receptor da interleucina-4 (il-4r) para uso no tratamento de asma moderada a grave ou grave em um indivíduo
TR201819492T4 (tr) Bir ıl-4r antagonisti uygulayarak astımı tedavi etmek veya önlemek için yöntemler.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]